vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and SB FINANCIAL GROUP, INC. (SBFG). Click either name above to swap in a different company.

SB FINANCIAL GROUP, INC. is the larger business by last-quarter revenue ($16.4M vs $13.5M, roughly 1.2× Assertio Holdings, Inc.). On growth, SB FINANCIAL GROUP, INC. posted the faster year-over-year revenue change (6.3% vs -57.9%). Over the past eight quarters, SB FINANCIAL GROUP, INC.'s revenue compounded faster (11.8% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

SB Financial Group, Inc. is a U.S.-headquartered financial holding company that provides a full suite of personal and commercial banking products and services, including deposit accounts, mortgage and consumer loans, small business financing, and wealth management solutions. It primarily serves retail customers and small to medium-sized enterprises across regional markets in the United States.

ASRT vs SBFG — Head-to-Head

Bigger by revenue
SBFG
SBFG
1.2× larger
SBFG
$16.4M
$13.5M
ASRT
Growing faster (revenue YoY)
SBFG
SBFG
+64.2% gap
SBFG
6.3%
-57.9%
ASRT
Faster 2-yr revenue CAGR
SBFG
SBFG
Annualised
SBFG
11.8%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
SBFG
SBFG
Revenue
$13.5M
$16.4M
Net Profit
$3.9M
Gross Margin
Operating Margin
-86.7%
30.3%
Net Margin
23.9%
Revenue YoY
-57.9%
6.3%
Net Profit YoY
7.8%
EPS (diluted)
$-4.54
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
SBFG
SBFG
Q4 25
$13.5M
$16.4M
Q3 25
$49.5M
$16.6M
Q2 25
$29.2M
$17.2M
Q1 25
$26.5M
$15.4M
Q4 24
$32.2M
$15.5M
Q3 24
$29.2M
$14.3M
Q2 24
$31.1M
$14.0M
Q1 24
$32.4M
$13.1M
Net Profit
ASRT
ASRT
SBFG
SBFG
Q4 25
$3.9M
Q3 25
$11.4M
$4.0M
Q2 25
$-16.4M
$3.9M
Q1 25
$-13.5M
$2.2M
Q4 24
$3.6M
Q3 24
$-2.9M
$2.4M
Q2 24
$-3.7M
$3.1M
Q1 24
$-4.5M
$2.4M
Operating Margin
ASRT
ASRT
SBFG
SBFG
Q4 25
-86.7%
30.3%
Q3 25
23.2%
29.9%
Q2 25
-27.5%
27.5%
Q1 25
-50.0%
16.8%
Q4 24
-41.9%
29.3%
Q3 24
-10.4%
21.7%
Q2 24
-11.6%
24.0%
Q1 24
-13.4%
21.7%
Net Margin
ASRT
ASRT
SBFG
SBFG
Q4 25
23.9%
Q3 25
23.1%
24.4%
Q2 25
-56.0%
22.4%
Q1 25
-51.1%
14.0%
Q4 24
23.5%
Q3 24
-10.0%
16.5%
Q2 24
-11.8%
22.2%
Q1 24
-13.9%
18.0%
EPS (diluted)
ASRT
ASRT
SBFG
SBFG
Q4 25
$-4.54
$0.62
Q3 25
$0.11
$0.64
Q2 25
$-0.17
$0.60
Q1 25
$-0.14
$0.33
Q4 24
$-3.28
$0.55
Q3 24
$-0.03
$0.35
Q2 24
$-0.04
$0.47
Q1 24
$-0.05
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
SBFG
SBFG
Cash + ST InvestmentsLiquidity on hand
$63.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$141.2M
Total Assets
$267.0M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
SBFG
SBFG
Q4 25
$63.4M
Q3 25
$93.4M
Q2 25
$98.2M
Q1 25
$87.3M
Q4 24
$100.1M
Q3 24
$88.6M
Q2 24
$88.4M
Q1 24
$80.7M
Total Debt
ASRT
ASRT
SBFG
SBFG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$19.7M
Q3 24
$19.7M
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
SBFG
SBFG
Q4 25
$94.0M
$141.2M
Q3 25
$105.8M
$136.9M
Q2 25
$93.3M
$133.6M
Q1 25
$108.5M
$131.5M
Q4 24
$121.1M
$127.5M
Q3 24
$130.5M
$132.8M
Q2 24
$132.2M
$125.5M
Q1 24
$134.5M
$123.7M
Total Assets
ASRT
ASRT
SBFG
SBFG
Q4 25
$267.0M
$1.5B
Q3 25
$319.8M
$1.5B
Q2 25
$273.8M
$1.5B
Q1 25
$286.4M
$1.5B
Q4 24
$284.7M
$1.4B
Q3 24
$276.0M
$1.4B
Q2 24
$279.4M
Q1 24
$282.0M
Debt / Equity
ASRT
ASRT
SBFG
SBFG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.15×
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
SBFG
SBFG
Operating Cash FlowLast quarter
$-30.0M
$24.0M
Free Cash FlowOCF − Capex
$21.4M
FCF MarginFCF / Revenue
130.6%
Capex IntensityCapex / Revenue
15.8%
Cash ConversionOCF / Net Profit
6.14×
TTM Free Cash FlowTrailing 4 quarters
$35.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
SBFG
SBFG
Q4 25
$-30.0M
$24.0M
Q3 25
$-4.8M
$12.7M
Q2 25
$19.1M
$-3.6M
Q1 25
$-12.5M
$6.7M
Q4 24
$11.5M
$9.5M
Q3 24
$-35.0K
$3.6M
Q2 24
$7.4M
$-434.0K
Q1 24
$7.5M
$308.0K
Free Cash Flow
ASRT
ASRT
SBFG
SBFG
Q4 25
$21.4M
Q3 25
$12.2M
Q2 25
$-4.2M
Q1 25
$5.8M
Q4 24
$8.2M
Q3 24
$3.2M
Q2 24
$-833.0K
Q1 24
$149.0K
FCF Margin
ASRT
ASRT
SBFG
SBFG
Q4 25
130.6%
Q3 25
73.8%
Q2 25
-24.2%
Q1 25
37.6%
Q4 24
53.2%
Q3 24
22.6%
Q2 24
-5.9%
Q1 24
1.1%
Capex Intensity
ASRT
ASRT
SBFG
SBFG
Q4 25
15.8%
Q3 25
2.7%
Q2 25
3.1%
Q1 25
6.0%
Q4 24
8.0%
Q3 24
0.0%
2.7%
Q2 24
2.8%
Q1 24
1.2%
Cash Conversion
ASRT
ASRT
SBFG
SBFG
Q4 25
6.14×
Q3 25
-0.42×
3.14×
Q2 25
-0.94×
Q1 25
3.11×
Q4 24
2.60×
Q3 24
1.54×
Q2 24
-0.14×
Q1 24
0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

SBFG
SBFG

Segment breakdown not available.

Related Comparisons